GlassScriptPhysician profile
William Dana Largen
NPI 1336435205
$6,088.43
in general payments reported to CMS, 2019-2025
20 companies · $660 in 2025
The $660 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,194 · 2020: $1,005 · 2021: $1,143 · 2022: $833 · 2023: $598 · 2024: $657 · 2025: $660.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,888 · Education: $25.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,888.19 |
| Education | $25.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $1,798.50 | 2019-2025 | Cabenuva, Rukobia, Dovato |
| Gilead Sciences, INC. | $932.11 | 2019-2025 | Biktarvy |
| Merck Sharp & Dohme LLC | $715.04 | 2019-2025 | Zerbaxa, Recarbrio, Dificid |
| Insmed, INC. | $526.37 | 2019-2025 | Arikayce |
| Shionogi INC | $416.72 | 2021-2025 | Fetroja |
| Abbvie INC. | $409.58 | 2019-2024 | |
| Paratek Pharmaceuticals, INC. | $321.14 | 2019-2025 | Nuzyra |
| Melinta Therapeutics, LLC | $226.50 | 2019-2025 | Kimyrsa, Vabomere, Rezzayo |
| Astellas Pharma US INC | $132.82 | 2020-2024 | Cresemba |
| Aimmune Therapeutics, INC. | $121.47 | 2025 | Zenpep, Vowst |
| Theratechnologies INC. | $119.99 | 2019-2023 | Trogarzo, Egrifta |
| Allergan, INC. | $90.95 | 2019-2020 | |
| Janssen Biotech, INC. | $84.42 | 2019-2022 | |
| Cumberland Pharmaceuticals, INC. | $47.22 | 2025 | Vibativ |
| Nabriva Therapeutics, Plc | $30.19 | 2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cormedix INC. | $28.65 | 2025 | Defencath |
| Janssen Scientific Affairs, LLC | $27.51 | 2019-2020 | |
| Tetraphase Pharmaceuticals, INC. | $26.19 | 2019 | |
| Pfizer INC. | $21.97 | 2023 | |
| Vyera Pharmaceuticals, LLC | $11.09 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Largen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.